the aclaris therapeutics ( n=19 ) earnings call is a transitional year in which we redefined our strategy and shifted our capital allocation to focus on our immuno-inflammatory pipeline. in this article we will discuss our current and ongoing efforts to develop kinase inhibitors for immuno-inflammatory diseases. we will also discuss the pipeline update and the financial updates.